Cirrhotic cardiomyopathy: a cardiologist's perspective

Area of Science:

• Cardiology
• Hepatology
• Pharmacology

Background:

• Cardiac dysfunction is common in cirrhosis, historically attributed to alcohol but now recognized as cirrhotic cardiomyopathy (CCM) regardless of etiology.
• CCM is characterized by hyperdynamic circulation and complex pathophysiological mechanisms involving neurohumoral pathways, cellular signaling, and altered cardiomyocyte physiology.
• Key clinical features include systolic and diastolic dysfunction, electrical abnormalities, and chronotropic incompetence, with diastolic dysfunction being particularly prominent.

Purpose of the Study:

• To review the pathophysiological basis of cirrhotic cardiomyopathy (CCM).
• To outline the clinical features associated with CCM.
• To discuss current therapeutic options for CCM.

Main Methods:

• Review of existing literature on cirrhotic cardiomyopathy.
• Analysis of pathophysiological mechanisms including neurohumoral and cellular pathways.
• Compilation of clinical manifestations and current treatment strategies.

Main Results:

• CCM involves impaired beta-receptor and calcium signaling, altered cardiomyocyte membrane function, elevated sympathetic tone, and increased vasodilatory pathways.
• Diastolic dysfunction in CCM stems from increased myocardial stiffness due to hypertrophy, fibrosis, and edema, leading to elevated cardiac filling pressures.
• Liver transplantation is the sole effective therapy, capable of reversing cardiac dysfunction in end-stage liver disease.

Conclusions:

• Cirrhotic cardiomyopathy is a distinct entity with complex underlying mechanisms and significant clinical manifestations.
• Current therapeutic options for CCM are limited, with liver transplantation offering the only established effective treatment.
• Further research into CCM pathogenesis and targeted therapies is warranted.